Basilea News http://www.basilea.com/ Basilea News en Tue, 09 Feb 2016 10:33:15 +0100 Tue, 09 Feb 2016 10:33:15 +0100 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program]]> http://www.basilea.com/News-and-Media/GSK-informs-Basilea-that-it-has-elected-not-to-continue-its-U-S-alitretinoin-program/b83c1ac3-cb42-0ed3-166d-4383646bf464 Thu, 21 Jan 2016 21:15:45 +0100 http://www.basilea.com/News-and-Media/GSK-informs-Basilea-that-it-has-elected-not-to-continue-its-U-S-alitretinoin-program/b83c1ac3-cb42-0ed3-166d-4383646bf464 <![CDATA[Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor]]> http://www.basilea.com/News-and-Media/Basileas-Head-of-Global-Human-Resources-Heidi-Mc-Daid-to-retire-and-Ursula-Eberhardt-named-as-successor/e8003380-eef6-741c-3533-6c321efba70a Tue, 29 Dec 2015 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basileas-Head-of-Global-Human-Resources-Heidi-Mc-Daid-to-retire-and-Ursula-Eberhardt-named-as-successor/e8003380-eef6-741c-3533-6c321efba70a <![CDATA[Basilea provides clinical program updates]]> http://www.basilea.com/News-and-Media/Basilea-provides-clinical-program-updates/df42cebe-ee27-a8dc-3ba8-198e4fe19d1f This press release or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan and does not constitute an offer of securities for sale in such countries

  • Ceftobiprole U.S. clinical phase 3 program discussed with FDA
  • Interim data from phase 1/2a study with tumor checkpoint controller BAL101553 show signals of clinical benefit
]]>
Mon, 28 Dec 2015 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-provides-clinical-program-updates/df42cebe-ee27-a8dc-3ba8-198e4fe19d1f
<![CDATA[Final allocations of Basilea CHF 200 million senior convertible bonds]]> http://www.basilea.com/News-and-Media/Final-allocations-of-Basilea-CHF-200-million-senior-convertible-bonds/7228dbac-c55a-59de-f4c9-6c638a573737 Fri, 18 Dec 2015 18:42:33 +0100 http://www.basilea.com/News-and-Media/Final-allocations-of-Basilea-CHF-200-million-senior-convertible-bonds/7228dbac-c55a-59de-f4c9-6c638a573737 <![CDATA[Basilea successfully places CHF 200 million senior convertible bonds]]> http://www.basilea.com/News-and-Media/Basilea-successfully-places-CHF-200-million-senior-convertible-bonds/e7bcd0fb-1b22-b2da-2473-f976bfcaede6 Wed, 09 Dec 2015 17:19:36 +0100 http://www.basilea.com/News-and-Media/Basilea-successfully-places-CHF-200-million-senior-convertible-bonds/e7bcd0fb-1b22-b2da-2473-f976bfcaede6 <![CDATA[Basilea launches a senior convertible bond issue]]> http://www.basilea.com/News-and-Media/Basilea-launches-a-senior-convertible-bond-issue/c1325bbf-88d7-fc06-4ae4-1582e1b01734 Wed, 09 Dec 2015 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-launches-a-senior-convertible-bond-issue/c1325bbf-88d7-fc06-4ae4-1582e1b01734 <![CDATA[Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553]]> http://www.basilea.com/News-and-Media/Basilea-to-present-preclinical-brain-tumor-stem-cell-data-on-its-oncology-drug-candidate-BAL101553/a31834ec-1518-9921-9875-009bccfa2631
  • Tumor check point controller BAL101553 demonstrates inhibitory activity on tumor stem cell self-renewal and invasion in models of brain cancer
  • Loss of glioblastoma stem cell properties induced by BAL101553 correlates with EB1 expression levels in vitro and in animal models
  • ]]>
    Thu, 05 Nov 2015 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-to-present-preclinical-brain-tumor-stem-cell-data-on-its-oncology-drug-candidate-BAL101553/a31834ec-1518-9921-9875-009bccfa2631
    <![CDATA[Basilea announces that European Commission maintained isavuconazole's orphan drug status]]> http://www.basilea.com/News-and-Media/Basilea-announces-that-European-Commission-maintained-isavuconazoles-orphan-drug-status/cd22615f-04d3-50c8-ca41-9f20ee7988e3 Fri, 23 Oct 2015 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-that-European-Commission-maintained-isavuconazoles-orphan-drug-status/cd22615f-04d3-50c8-ca41-9f20ee7988e3 <![CDATA[Basilea announces filing of registration statement for a proposed offering in the United States]]> http://www.basilea.com/News-and-Media/Basilea-announces-filing-of-registration-statement-for-a-proposed-offering-in-the-United-States/49bdc96b-549c-4bee-eb6d-b544d78e8322
  • Basilea seeks access to U.S. public equity market
  • The offering is intended to:
    • increase liquidity, visibility and coverage for Basilea shares
    • facilitate Basilea's participation in ceftobiprole phase 3 development program to gain U.S. regulatory approval
    • support commercialization activities of ceftobiprole and
      isavuconazole, and
    • further advance Basilea's research and development projects
    ]]> Fri, 16 Oct 2015 20:43:23 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-filing-of-registration-statement-for-a-proposed-offering-in-the-United-States/49bdc96b-549c-4bee-eb6d-b544d78e8322 <![CDATA[Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union]]> http://www.basilea.com/News-and-Media/Basilea-announces-that-European-Commission-approves-isavuconazole-CRESEMBA-as-a-treatment-for-invasive-aspergillosis-and-mucormycosis-in-the-European-Union/1c973f43-6bf6-e9c0-acc7-a28994a4cbc3
  • Basilea's second anti-infective product approved in Europe, providing potential commercial synergy with Zevtera┬« (ceftobiprole)
  • ]]>
    Fri, 16 Oct 2015 16:48:05 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-that-European-Commission-approves-isavuconazole-CRESEMBA-as-a-treatment-for-invasive-aspergillosis-and-mucormycosis-in-the-European-Union/1c973f43-6bf6-e9c0-acc7-a28994a4cbc3